> some short-term disruption but no lasting damage
Overall this is correct.
The only exception I could think of: Abbvie reacted more strongly than other pharma companies in the after-hourse trading on the day of the announcement. In a way this makes sense.
If your only lead product's sales depend much on being listed as preferred in many formularies (made possible by kickback payments), then you're a company to fear the end of rebates/safe-harbour protection of kickback payments.
Market Data 
Markets 
AI
